Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider trading notification and does not contain financial statements or performance metrics.
Material Changes
The only material change disclosed is a reduction in shareholding by Ms. C. Thomas. On September 22, 2009, she sold 2,868 Ordinary shares at a price of £12.14 per share. No other material changes to the company's operations or financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. The document strictly adheres to the requirements of Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of the share sale.
Key Facts for Investor Verification
- Transaction Date: September 22, 2009
- Individual: Ms. C. Thomas
- Action: Sale of 2,868 Ordinary shares
- Price: £12.14 per share
- Regulatory Basis: Notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a)